Long noncoding RNA PANDAR promotes progression and predicts poor prognosis via upregulating ROCK1 in prostate cancer
Authors: B Li
S Zhao
J Yang
Journal: European review for medical and pharmacological sciences (2019)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: lncRNA PANDAR; prostate cancer; tumorigenesis; RT-qPCR; disease-free survival
Affiliations: Department of Pathology, Jinzhou Medical University, Jinzhou, China. .

Abstract:  Objective: Recent researches have proved that long noncoding RNAs (lncRNAs) play an important role in tumorigenesis. In this research, lncRNA PANDAR was explored to identify the role it played in the development of prostate cancer and how it achieves. Patients and methods: Real-time quantitative polymerase chain reaction (RT-qPCR) was utilized to detect PANDAR expression in both prostate cancer tissue samples and cells. Moreover, the associations between expression level of PANDAR and patients' disease-free survival rate were studied respectively. Then wound healing assay and transwell assay were conducted. Furthermore, RT-qPCR and Western blot assay were used to explore the underlying mechanism. Results: By comparison with PANDAR expression in adjacent tissues, PANDAR expression level was significantly higher in prostate cancer samples, which was closely associated with patients' disease-free survival time. Moreover, after PANDAR was upregulated, cell migration and cell invasion capacities of prostate cancer cells were enhanced in vitro. In addition, after overexpression of PANDAR, the mRNA and protein expression of ROCK1 was upregulated, respectively. Furthermore, it was found that ROCK1 expression was positively correlated to PANDAR expression in prostate cancer tissues. Conclusions: Results above suggest that PANDAR could enhance cell migration and invasion of prostate cancer by upregulating ROCK1, which may offer a potential therapeutic target in prostate cancer. 

Retracted: Yes

PubPeer comments:
 This paper is one of a set of 121 papers that all contain images from the same library of about 100 photos and plots. This is unexpected, because each paper has different authors and different affiliations, with little to no overlap, and describes different cancer types and molecules. It would be very hard to explain how authors from different labs would all obtain the same photo. Therefore, the papers might have all be derived from the same source, such as a paper mill that sells ready-to-be-published papers. This  Stock Photo paper set has been described in more detail on my blog post, https: scienceintegritydigest.com 2020 07 05 the-stock-photo-paper-mill and in a Wall Street Journal article by Eva Xiao (currently behind a paywall): https: www.wsj.com articles chinese-research-papers-raise-doubts-fueling-global-questions-about-scientific-integrity-11593939600 The vast majority (113 121) of the papers were published in the same journal, European Review for Medical and Pharmacological Sciences (ERMPS). A link to the full set of papers can be found here: https: docs.google.com spreadsheets d 172RWS18w1lTNJ9Nnj80fuXXTqTm4fGkoK0sdYyvKE3g edit?usp=sharing All papers have been reported to the journal editors on July 2, 2020. , 
 An additional concern: Figure 3 shows two panels that not only both match the 100 photos in the Stock Photo library, but that also appear to overlap with each other. Both are showing the  TW13 Spooky Paramount Footstep photo. Overlap shown with red boxes. ![file] , 
 Withdrawn. https: www.europeanreview.org article 23755 *Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, u201cLong noncoding RNA PANDAR promotes progression and predicts poor prognosis via upregulating ROCK1 in prostate cancer, by J. Yang, S. Zhao, B. Li, published in Eur Rev Med Pharmacol Sci 2019; 23 (11): 4706-4712u2013DOI: 10.26355 eurrev_201906_18051u2013PMID: 31210296u201d has been withdrawn.* *The Publisher apologizes for any inconvenience this may cause.* ,